Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.79, read 2026-11-04
Ethical does not pass the values gate
Price39.11 USD
Fair value42.00Our model only; only one analyst covers it, too few to cross-check it.
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-11-02Read Markup38.25+2.2% to today ✓Distribution gives way to Markup
2026-10-26Read Distribution37.68+3.8% to today Markdown gives way to Distribution after a 14% slide in 6 weeks
2026-09-15Read Markdown43.84-10.8% to today ✓Distribution gives way to Markdown first Markdown read since July
2026-08-15Read Distribution43.84-10.8% to today ✓Markdown gives way to Distribution after a 9% rise in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Universal Health Realty Income Trust holds its Markup at $39.11. Consolidating, no directional conviction, held for 570 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 570 days
Price at the screen
$39.11
Valuation
31.09 trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
68.34%
Below 33%
Interest-bearing debt is 68.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
3.94%
Below 49%
Money owed to the company is 3.9% of assets, under the 49% limit.
Pass
Revenue purity
3.05%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Universal Health Realty Income Trust's business is in a permissible area, but its interest-bearing debt is about 68% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UHT's ethical verdict changes
Today UHT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 7% discount to our $42.00 fair value, none competitive moat, 0.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 6.9% discount to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Where our models see it going: fair-value estimate $42.00, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it is worth knowing
A quality business: a none moat and 18% profit margins. It trades close to our $42.00 fair value, so the easy discount is gone; you would be paying up for the quality.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UHT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-02Markup · changed$38.25+1.5%Entry 16
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$37.68+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$37.68+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$37.68+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$37.68+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$37.68+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$37.68+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$37.68+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$37.68-5.3%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (1 analysts) rates it none, with a mean price target of $42.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.